Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Vaccination against Onchocerca volvulus induces IgG-mediated protective immunity dependent on neutrophils and complement

ABSTRACT: Onchocerciasis remains a significant cause of morbidity and economic loss in sub-Saharan Africa. Despite the existence of effective therapeutics, a prophylactic vaccine targeting the etiologic agent, Onchocerca volvulus, is needed to control ongoing disease and transmission. Mice were vaccinated against O. volvulus with a fusion of the recombinant antigens Ov-103 and Ov-RAL-2 (Ov-FUS-1) with Advax-CpG adjuvant. Immunized mice developed protective immunity with the killing of third-stage larvae (L3) within 36 hours of challenge infection. IgG from immunized mice passively transferred protective immunity to naïve mice, indicating that antigen-specific IgG mediated parasite elimination. Neutrophils were the most abundant subset of immune cells recruited to the parasite microenvironment in vivo, and their depletion resulted in the total loss of immune-mediated larval killing. Analysis of neutrophil gene expression revealed that both vaccination and the presence of O. volvulus larvae were capable of modulating neutrophil transcriptional activity. The mechanism by which antigen-specific IgG and neutrophils collaborated to kill L3 was independent of Fcγ receptors. However, the elimination of complement component C3 prevented vaccine-induced protection, which suggests these components may interact through the complement system. This study describes a vaccine-induced mechanism of protective immunity against O. volvulus L3 dependent on IgG, neutrophils, and complement, highlighting an effective collaboration between the innate and adaptive arms of the immune system to control O. volvulus infection.

ORGANISM(S): Mus musculus

PROVIDER: GSE295728 | GEO | 2025/09/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Rapid protection induced by a single-shot Lassa vaccine in cynomolgus monkeys

Project description:Lassa fever outbreaks hit West African countries every year and there is still no licensed vaccine to limit the burden of this viral hemorrhagic fever. We previously developed MeV-NP, a single-shot vaccine that induces protective immunity in cynomolgus monkeys one month or more than a year before Lassa virus infection and that is able to protect against divergent viral strains. Given the limited dissemination area of Lassa virus during outbreaks and the high risk of nosocomial transmission, a vaccine that induces rapid protection could be useful to protect exposed people during outbreaks in the absence of preventive vaccination. We tested whether the time to protection could be reduced after immunization by challenging MeV pre-immune cynomolgus monkeys 16 or 8 days after a single shot of MeV-NP. None of the immunized monkeys developed disease and they rapidly controlled viral replication. Animals immunized eight days before the challenge were the best controllers, producing a strong CD8 T-cell response against the viral glycoprotein. A group of animals was also vaccinated an hour after the challenge. These animals did not develop any protective immune responses and presented the same lethal disease as the control animals. This study demonstrates that MeV-NP can induce a rapid protective immune response against Lassa fever in presence of MeV pre-existing immunity but can likely not be used as therapeutic vaccine.

2023-02-21 | GSE225258 | GEO

Immunosignatures can predict vaccine efficacy

2013-11-04 | GSE51623 | GEO

Protective response to Brucella infection

Project description:Brucella ovis causes an important disease characterized by decreased fertility in rams, sporadic abortions in ewes and increased lamb mortality. The live attenuated B. melitensis Rev.1 vaccine is considered the best vaccine available against this infection. However, this vaccine shows variable protective efficacy ranging from 40% to 100%.The objective of this study was to identify possible correlates of protective response to B. ovis infection through the characterization by microarray hybridization and real-time RT-PCR of inflammatory and immune response genes upregulated in rams previously immunized with the B. melitensis Rev 1 vaccine strain and experimentally challenged with B. ovis. Gene expression profiles were compared before and after challenge with B. ovis between rams protected and those vaccinated but found infected after challenge. The genes upregulated in vaccinated and protected rams provide possible correlates of protective response to B. ovis infection in rams immunized with the B. melitensis Rev 1 vaccine. Gene expression profiles were compared before and after vaccination and challenge with B. ovis between rams protected with the B. melitensis Rev 1 vaccine strain and those vaccinated but infected after challenge. Total RNA was isolated from buffy coat samples before vaccination (T0), after vaccination and before challenge (T1) and 60 days post challenge (T2) using TriReagent (Sigma, St. Louis, MO, USA)

2010-06-25 | E-GEOD-13202 | biostudies-arrayexpress

H11-induced immune protection is predominantly linked to N-glycan moieties

Project description:Parasitic nematodes of humans, animals and plants cause significant economic losses worldwide. Control of these pathogens is currently challenging due to the widespread problem of nematode anthelmintic resistance. Unfortunately, most efforts to develop anti-nematode vaccines for use in animals and humans have not succeeded. However, one effective (dead) anti-nematode vaccine (Barbervax) has been developed to protect livestock animals against the socioeconomically important parasitic nematode Haemonchus contortus (barber’s pole worm). This vaccine contains a major native antigen, termed H11. In its native form, H11 alone consistently induces high immunoprotection (75-95%) in animals, but recombinant forms thereof do not. Here, to test the hypothesis that post-translation modification of H11 is responsible for achieving the immunoprotection. We explored the N-glycoproteome and N-glycome of H11 using high-resolution mass spectrometry and assessed the roles of N-glycosylation in protective immunity against H. contortus. We demonstrated that N-glycans are a predominant protective component that induces protection and an associated IgG antibody response in immunised animals. We also showed that anti-H11 IgG antibodies confer specific, passive immunity in naïve animals. This study is the first detailed investigation of the relevance of protein glycosylation in protective immunity against a parasitic nematode, and should have important implications for developing vaccines against metazoan parasites.

2022-10-20 | PXD037140 | Pride

Protective response to Brucella infection

2008-10-17 | GSE13202 | GEO

Immunosignatures can predict vaccine efficacy

Project description:Mice were immunized with either formalin fixed Influenza A/PR/8/34 (Killed PR8), the 2006-2007 seasonal influenza vaccine, the 2007-2008 seasonal influenza vaccine, a sublethal infection (live PR8) or mock immunized (PBS). Array data was used to distinguish the immunogens from each other and predict which of the three inactivated vaccines would be protective against A/PR/8/34 challenge. two replicates of each peptide was printed on 1 CIM_10kv3 peptide microarray. One microarray were tested for each sample. Image was qualified using in-house metrics for quality assurance.

2013-11-04 | E-GEOD-51623 | biostudies-arrayexpress

Mouse ear tissue at 21 days post immunization

Project description:Gene expression analysis using nCounter immunology panel for profiling among naïve controls and immunized treatment samples. We explored the interplay between type-I IFNs and the development of host protective Th1 immunity in mice immunized with LmCen-/- parasites and challenged with L. donovani parasites and show that downregulation of IRF7 mediated production of IFN-α/β is critical for the induction of protective immunity.

2023-04-29 | GSE230927 | GEO

Mouse ear tissue at 7 days post immunization

Project description:Gene expression analysis using NanoString nCounter immunology panel for profiling among naïve controls and immunized treatment samples. We explored the interplay between type-I IFNs and the development of host protective Th1 immunity in mice immunized with LmCen-/- parasites and challenged with L. donovani parasites and show that downregulation of IRF7 mediated production of IFN-α/β is critical for the induction of protective immunity.

2023-04-29 | GSE230924 | GEO

Mouse ear tissue at 2 days post immunization

2023-04-29 | GSE230920 | GEO

Mass spectrometry of circulating antigens products isolated from sera of mice infected with Toxoplasma gondii tachyzoites

Project description:Toxoplasma gondii is a ubiquitous apicomplexan protozoan parasite that can infect all warm-blooded animals and lead to toxoplasmosis. Discovering efficient methods for diagnosing T. gondii infection and developing vaccine candidates are essential for controlling this disease. Circulating antigens (CAg) are reliable diagnostic indicators of acute infection and highly immunogenic compounds that induce protective immunity. We aimed to identify the CAg spectrum in infected mouse serum. Among 31 identified CAg, we evaluated the ability of RuvB-like helicase (TgRuvBL1), ribonuclease (TgRNaseH1), and ribosomal protein RPS2 (TgRPS2) to protect against T. gondii infection. These three proteins were found in the serum of infected mice. Vaccination with rTgRuvBL1 or rTgRPS2 elicited powerful humoral and cellular immune responses in mice, as levels of total IgG, IgG2a, IgG1, and CD4+ and CD8+ T lymphocytes were significantly increased. The production of proinﬂammatory gamma-interferon, interleukin-2, and interleukin-12 was also significantly increased. The survival of mice immunized with rTgRuvBL1 (10.0 ± 0.30 days) or rTgRPS2 (11.5 ± 0.34 days) was significantly prolonged after challenge with virulent T. gondii RH strain (P < 0.05 vs. control). The three proteins are potential diagnostic candidates for acute T. gondii and TgRuvBL1 and TgRPS2 might serve as candidate vaccine antigens against toxoplasmosis.

2021-01-04 | PXD021938 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data